Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis

Circulation

Volumn 93, Issue 10, 1996, Pages 1913-1918

  Ragni, Massimo ^a   Cirillo, Plinio ^a   Pascucci, Immacolata ^a   Scognamiglio, Annalisa ^a   D'Andrea, Davide ^a   Eramo, Nicola ^a   Ezekowitz, Michael D ^b   Pawashe, Aruna B ^b   Chiariello, Massimo ^a   Golino, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

coagulation; thrombolysis; tissue factor

Indexed keywords

MONOCLONAL ANTIBODY; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CAROTID ARTERY FLOW; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; HEART MUSCLE REPERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION;

EID: 9344230339     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.10.1913     Document Type: Article

References (34)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI). Effectiveness of thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin or neither among 17187 cases of suspected acute myocardial infarction: ISIS 2. Lancet. 1988;4:340-360.
4. Verstraete M, Bleifeld W, Brower RW, Charbonnier B, Collen D, deBono DP, Dunning AJ, Lennane RJ, Lubsen J, Mathey DG, Michel PL, Rayaud PH, Schofer J, Vahanian A, Vanhaecke J, van de Kley GA, van de Werf, von Essen R. Double-blind randomized trial of IV tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985;2:965-969.
5. Neuhaus KL, Tebbe U, Gotturik M. IV recombinant TPA and urokinase in acute myocardial infarction: results of the German Urokinase Study (GAUS). J Am Coll Cardiol. 1988;12:1045-1056.
6. Verstraete M, Bernard R, Bory M. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator. Lancet. 1985;1:545-549.
7. Chesebro JH, Knatterud G, Roberts R. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 1987;76:142-154.
8. Reimer KA, Jennings JB. The 'wavefront phenomenon' of myocardial ischemic cell death, II: transmural progression of necrosis within the framework of the ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;75:817-829.
9. Bush LR, Samowitz W, Buja LM, Rude RE, Willerson JT. Recovery of left ventricular function after long-term reperfusion following temporary coronary occlusion in conscious dogs: comparison of 2- and 4-hour occlusion. Circ Res. 1983;53:248-263.
10. Bush LR, Buja LM, Tilton G, Wathen M, Apprill P, Ashton JH, Willerson JT. Effects of propanolol and diltiazem alone and in combination on the recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Circulation. 1985;72:413-430.
11. Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation. 1986;74:583-587.
12. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988;77: 670-677.
13. 2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation. 1989;79:911-919.
14. Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. J Clin Invest. 1990;86:1095-1102.
15. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation. 1988; 77:678-684.
16. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;12:1111-1121.
17. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK, Ezekowitz MD. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res. 1994;74:56-63.
18. Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843.
19. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91: 619-622.
20. Golino P, Willerson JT. Is thrombolysis alone the best therapy for acute myocardial infarction? Tex Heart Inst J. 1991;18:50-61.
21. Fenton JW, Ofosu FA, Moon DG, Maraganore JM. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagul Fibrinolysis. 1991;2:69-75.
22. Golino P, Ambrosio G, Pascucci I, Ragni M, Russolillo E, Chiariello M. Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation. Thromb Haemost. 1992;67:302-305.
23. Golino P, Cappelli-Bigazzi M, Ambrosio G, Ragni M, Russolillo E, Condorelli M, Chiariello M. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res. 1992;71:1447-1456.
24. Davies MJ, Woolf N. Atherosclerosis: what is it and why does it occur? Br Heart J. 1993;69(suppl):S3-S11.
25. 111In-platelet deposition in baboons. Arteriosclerosis. 1986;6:511-518.
26. Salimi A, Oliver GC Jr, Lee J, Sherman LA. Continued incorporation of circulating radiolabeled fibrinogen into preformed coronary artery thrombi. Circulation. 1977;56:213-220.
27. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol. 1987;10:527-529.
28. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90:1522-1536.
29. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost. 1992;68: 64-68.
30. Haskel EJ, Prager NA, Sobel BE, Abenschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
31. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23: 993-1003.
32. Lee LV, McCabe CH, Antman EM, Koch M, Wilensky R, Stringer K, Hochman J, Mueller HS, Henry TD, Kleiman N, Steingart RM, Wasserman H, for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI 6 trial. J Am Coll Cardiol. 1994;(special issue):344A. Abstract.
33. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87:1622-1629.
34. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;19:1065-1069.